5-(4-nitrophenyl)-1-phenyl-1H-pyrazole | 62089-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-nitrophenyl)-1-phenyl-1H-pyrazole
• 英文别名: 5-(4-nitrophenyl)-1-phenylpyrazole
• CAS: 62089-28-5
• 化学式: C₁₅H₁₁N₃O₂
• 分子量: 265.271
• InChiKey: YZWANVMVDZKGCA-UHFFFAOYSA-N

物化性质

• 熔点：
  93 °C
• 沸点：
  448.9±20.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-nitrophenyl)-1-phenyl-1H-pyrazole 在 potassium permanganate 、 乙醇 、 硫酸 、 溶剂黄146 、 锌 作用下， 生成 1-苯基-1H-吡唑-5-羧酸
  参考文献：
  名称：

  Cusmano, Gazzetta Chimica Italiana, 1940, vol. 70, p. 240,244

  摘要：

  DOI：
• 作为产物：
  描述：

  5-(4-硝基苯基)异噁唑-3-羧酸 在 乙醇 、 铜 作用下， 生成 5-(4-nitrophenyl)-1-phenyl-1H-pyrazole
  参考文献：
  名称：

  Cusmano, Gazzetta Chimica Italiana, 1940, vol. 70, p. 240,244

  摘要：

  DOI：

文献信息

• [EN] BENZISOXAZOLE MODULATORS OF NEUROGENESIS<br/>[FR] MODULATEURS BENZISOXAZOLE DE LA NEUROGÉNÈSE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014016267A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of general formula (I) wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole,3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5-yl)-. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式（I）的化合物，其中Ar1/Ar2为苯基或5或6-成员杂环芳基；R1/R2为氢、卤素、较低烷基、三氟甲基或较低烷氧基；n、m为1或2；或者为药学上可接受的酸盐加合物，为外消旋混合物或其相应的对映体和/或光学异构体，但不包括化合物2,1-苯并异噁唑，3-(4-氯苯基)-5-(1-苯基-1H-吡唑-5-基)-。这些化合物可用于治疗精神分裂症、强迫性人格障碍、重性抑郁症、躁郁症、焦虑障碍、正常衰老、癫痫、视网膜退行性疾病、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍、唐氏综合征、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化、亨廷顿病、中风、放射治疗、慢性应激、滥用神经活性药物，如酒精、鸦片类药物、甲基苯丙胺、非那西丁和可卡因。
• Ultrasound Assisted Synthesis of 1,5-Disubstituted Pyrazole using Cu(I) Catalyst
  作者：Ashok S. Pise、Arvind S. Burungale、Santosh S. Devkate

  DOI：10.14233/ajchem.2020.22432

  日期：2020.2.10

  A new efficient and convenient approach towards the synthesis of pyrazole is described. The α,β-unsaturated cyanoesters were obtained from substituted benzaldehyde and ethyl cyanoacetate by reported methods. 1,5-Disubstituted pyrazoles were synthesized from α,β-unsaturated cyanoester and phenyl hydrazine using sodium ethoxide as a base in the presence of 10 mol % Cu(I) catalyst in high yields within

  描述了一种新的有效且方便的合成吡唑的方法。采用已报道的方法由取代苯甲醛和氰基乙酸乙酯合成α,β-不饱和氰基酯。以乙醇钠为碱，在 10 mol% Cu(I) 催化剂存在下，在 60 ℃ 超声波照射下，75-90 分钟内以高产率合成 1,5-二取代吡唑，由 α,β-不饱和氰酯和苯肼合成。与传统方法相比，在超声波照射下反应速率大大提高，并且产率有所提高。
• BENZISOXAZOLES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150259334A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds of general formula wherein Ar 1 /Ar 2 are phenyl or a 5 or 6-membered heteroaryl; R 1 /R 2 is hydrogen, halogen, lower alkyl, CF 3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole, 3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5 -yl)-. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式为的化合物 其中Ar1/Ar2是苯基或5或6成员杂环基；R1/R2是氢、卤素、低碳基、CF3或低烷氧基；n，m为1或2；或其药学上可接受的酸盐、外消旋体混合物或其相应的对映异构体，但不包括化合物2,1-苯并异噁唑，3-(4-氯苯基)-5-(1-苯基-1H-吡唑-5-基)-。这些化合物可用于治疗精神分裂症、强迫性人格障碍、重度抑郁症、双相情感障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩性侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用，如酒精、鸦片类、甲基苯丙胺、邻-二氯苯基环已酮和可卡因。
• Benzisoxazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US09440962B2

  公开（公告）日：2016-09-13

  The present invention relates to compounds of general formula wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole, 3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5 -yl)-. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及通式的化合物，其中Ar1/Ar2是苯或5或6元杂环芳基；R1/R2是氢、卤素、低碳基、CF3或低碳氧基；n，m为1或2；或其对应的对映体和/或光学异构体的药学上可接受的酸加成盐，但不包括化合物2,1-苯并异噁唑，3-(4-氯苯基)-5-(1-苯基-1H-吡唑-5-基)-。这些化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、躁郁症、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑性共济失调、肌萎缩性侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、神经活性药物的滥用，如酒精、阿片类、甲基苯丙胺、苯环已啶和可卡因。
• Shetty, Shobhitha; Asma; Kalluraya, Balakrishna, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2016, vol. 55B, # 4, p. 501 - 506
  作者：Shetty, Shobhitha、Asma、Kalluraya, Balakrishna

  DOI：——

  日期：——